Rieder projected a promising outlook for the financial markets and the U.S. economy, suggesting that the S&P 500 could surpass the 5,300-point mark by the end of the year.
Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS® (sotorasib) with carboplatin and pemetrexed in adult